FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2616842406> ?p ?o ?g. }

• W2616842406 abstract "Selective serotonin reuptake inhibitors (SSRIs) are the only effective pharmacological treatments for obsessive-compulsive disorder (OCD). Nonetheless, their generally limited efficacy, side-effects, and delayed onset of action require improved medications for this highly prevalent disorder. Preclinical and clinical findings have suggested serotonin2C (5-HT2C) receptors as a potential drug target. Data in rats and mice are presented here on the effects of a novel 5-HT2C receptor agonist ((3S)-3-Methyl-1-[4-(trifluoromethyl)-7-benzofuranyl]-piperazine) (CPD 1) with high potency and full efficacy at 5-HT2C receptors and less potency and partial agonism at 5-HT2A and 5-HT2B receptors. Effects of CPD 1 on consummatory (schedule-induced polydipsia in rats) and non-consummatory behaviors (marble-burying and nestlet-shredding in mice) that are repetitive and non-habituating were studied. We also evaluated the effects of CPD 1 in rats with isoproterenol- and deprivation-induced drinking in rats to compare with the polydipsia studies. The SSRIs, fluoxetine, and chlomipramine decreased the high rates of drinking in rats engendered by a schedule of intermittent food delivery (schedule-induced polydipsia). The effects of fluoxetine, but not of d-amphetamine, were prevented by the selective 5-HT2C receptor antagonist SB242084. The 5-HT2C receptor agonists Ro 60-0175 and CPD 1 also decreased drinking, but unlike the SSRIs and Ro 60-0175, CPD 1 dose-dependently decreased excessive drinking without affecting lever press responses that produced food. The effects of CPD 1 were prevented by SB242084. CPD 1 also suppressed drinking induced by isoproterenol and by water deprivation without affecting normative drinking behavior. CPD 1, like fluoxetine, also suppressed marble-burying and nestlet-shredding in mice at doses that did not affect rotarod performance or locomotor activity. The behavioral specificity of effects of CPD 1 against repetitive and excessive behaviors suggests a potential therapeutic application in OCD." @default.
• W2616842406 created "2017-05-26" @default.
• W2616842406 creator A5000414432 @default.
• W2616842406 creator A5003115433 @default.
• W2616842406 creator A5019135645 @default.
• W2616842406 creator A5022661281 @default.
• W2616842406 creator A5035151398 @default.
• W2616842406 creator A5062055094 @default.
• W2616842406 creator A5079738340 @default.
• W2616842406 creator A5081330625 @default.
• W2616842406 creator A5090899159 @default.
• W2616842406 date "2017-05-22" @default.
• W2616842406 modified "2023-10-18" @default.
• W2616842406 title "Behavioral Effects of a Novel Benzofuranyl-Piperazine Serotonin-2C Receptor Agonist Suggest a Potential Therapeutic Application in the Treatment of Obsessive–Compulsive Disorder" @default.
• W2616842406 cites W1964322969 @default.
• W2616842406 cites W1975008955 @default.
• W2616842406 cites W1986420342 @default.
• W2616842406 cites W1995462339 @default.
• W2616842406 cites W2000928189 @default.
• W2616842406 cites W2013354438 @default.
• W2616842406 cites W2022106712 @default.
• W2616842406 cites W2029338703 @default.
• W2616842406 cites W2047576371 @default.
• W2616842406 cites W2058711118 @default.
• W2616842406 cites W2065071991 @default.
• W2616842406 cites W2079825367 @default.
• W2616842406 cites W2082386296 @default.
• W2616842406 cites W2089210700 @default.
• W2616842406 cites W2100861230 @default.
• W2616842406 cites W2122332152 @default.
• W2616842406 cites W2127700677 @default.
• W2616842406 cites W2128909808 @default.
• W2616842406 cites W2134923721 @default.
• W2616842406 cites W2152826712 @default.
• W2616842406 cites W2204386123 @default.
• W2616842406 cites W2234419073 @default.
• W2616842406 cites W2269715035 @default.
• W2616842406 cites W2411993022 @default.
• W2616842406 doi "https://doi.org/10.3389/fpsyt.2017.00089" @default.
• W2616842406 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5438973" @default.
• W2616842406 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28588509" @default.
• W2616842406 hasPublicationYear "2017" @default.
• W2616842406 type Work @default.
• W2616842406 sameAs 2616842406 @default.
• W2616842406 citedByCount "12" @default.
• W2616842406 countsByYear W26168424062019 @default.
• W2616842406 countsByYear W26168424062020 @default.
• W2616842406 countsByYear W26168424062021 @default.
• W2616842406 countsByYear W26168424062022 @default.
• W2616842406 countsByYear W26168424062023 @default.
• W2616842406 crossrefType "journal-article" @default.
• W2616842406 hasAuthorship W2616842406A5000414432 @default.
• W2616842406 hasAuthorship W2616842406A5003115433 @default.
• W2616842406 hasAuthorship W2616842406A5019135645 @default.
• W2616842406 hasAuthorship W2616842406A5022661281 @default.
• W2616842406 hasAuthorship W2616842406A5035151398 @default.
• W2616842406 hasAuthorship W2616842406A5062055094 @default.
• W2616842406 hasAuthorship W2616842406A5079738340 @default.
• W2616842406 hasAuthorship W2616842406A5081330625 @default.
• W2616842406 hasAuthorship W2616842406A5090899159 @default.
• W2616842406 hasBestOaLocation W26168424061 @default.
• W2616842406 hasConcept C126322002 @default.
• W2616842406 hasConcept C134018914 @default.
• W2616842406 hasConcept C15744967 @default.
• W2616842406 hasConcept C170493617 @default.
• W2616842406 hasConcept C2775864247 @default.
• W2616842406 hasConcept C2776134451 @default.
• W2616842406 hasConcept C2777193897 @default.
• W2616842406 hasConcept C2777450907 @default.
• W2616842406 hasConcept C2778938600 @default.
• W2616842406 hasConcept C2779624480 @default.
• W2616842406 hasConcept C513476851 @default.
• W2616842406 hasConcept C53910766 @default.
• W2616842406 hasConcept C555293320 @default.
• W2616842406 hasConcept C58732023 @default.
• W2616842406 hasConcept C71924100 @default.
• W2616842406 hasConcept C98274493 @default.
• W2616842406 hasConceptScore W2616842406C126322002 @default.
• W2616842406 hasConceptScore W2616842406C134018914 @default.
• W2616842406 hasConceptScore W2616842406C15744967 @default.
• W2616842406 hasConceptScore W2616842406C170493617 @default.
• W2616842406 hasConceptScore W2616842406C2775864247 @default.
• W2616842406 hasConceptScore W2616842406C2776134451 @default.
• W2616842406 hasConceptScore W2616842406C2777193897 @default.
• W2616842406 hasConceptScore W2616842406C2777450907 @default.
• W2616842406 hasConceptScore W2616842406C2778938600 @default.
• W2616842406 hasConceptScore W2616842406C2779624480 @default.
• W2616842406 hasConceptScore W2616842406C513476851 @default.
• W2616842406 hasConceptScore W2616842406C53910766 @default.
• W2616842406 hasConceptScore W2616842406C555293320 @default.
• W2616842406 hasConceptScore W2616842406C58732023 @default.
• W2616842406 hasConceptScore W2616842406C71924100 @default.
• W2616842406 hasConceptScore W2616842406C98274493 @default.
• W2616842406 hasFunder F4320307758 @default.
• W2616842406 hasLocation W26168424061 @default.
• W2616842406 hasLocation W26168424062 @default.
• W2616842406 hasLocation W26168424063 @default.
• W2616842406 hasLocation W26168424064 @default.
• W2616842406 hasOpenAccess W2616842406 @default.
• W2616842406 hasPrimaryLocation W26168424061 @default.

• next